Placebo News and Research

RSS

FDA advisory committee recommends that FDA wait for overall survival results from Satraplatin phase 3 trial

GPC Biotech AG has announced that the Oncologic Drugs Advisory Committee (ODAC) for the U.S. Food and Drug Administration (FDA) recommended (12-0) that the FDA should wait for the final survival analysis of the SPARC trial before deciding whether the satraplatin application is approvable for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy has failed.

25 Jul 2007

NSAIDs can reduce colorectal cancer risk

A study of Medicare patients with osteoarthritis provides additional evidence that non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin reduce the risk of colorectal cancer.

24 Jul 2007

Studies assess blood clot prevalence outside hospital prevention in hospital

More cases of venous thromboembolism are diagnosed in the three months following hospitalization than during hospitalization, but less than half of inpatients receive medications to prevent blood clots from occurring, according to a report in the July 23 issue of Archives of Internal Medicine.

24 Jul 2007

Hemoglobin-based oxygen carrier shows promise as treatment for sickle cell disease

Studies in mice suggest that a red blood cell substitute based on human hemoglobin could be a promising new treatment for sickle cell disease in humans.

24 Jul 2007

EpiCept to conduct Phase III study of EpiCept NP-1 for treatment of chemotherapy induced peripheral neuropathy

EpiCept Corporation has announced that it will study EpiCept NP-1, its patented topical cream formulation of two FDA-approved drugs, 4% amitriptyline and 2% ketamine, for the treatment of chemotherapy induced peripheral neuropathy (CPN) in the ATTRACT-CPN Phase III Study (Assessment of Topical Treatment Response with Amitriptyline and Ketamine: Combination Trial in Chemotherapy Peripheral Neuropathy).

23 Jul 2007

New drug shows promise in treating Crohn's disease

According to two new studies the drug certolizumab has proved to be a safe and effective treatment for moderate-to-severe Crohn's disease.

21 Jul 2007

D-Cycloserine found to help people with obsessive-compulsive disorder

Researchers at the University of Minnesota have found that a drug originally developed to fight tuberculosis may help people with obsessive-compulsive disorder make more progress in therapy sessions.

20 Jul 2007

Finasteride will cause little or no sexual dysfunction for most men who decide to take it

Men and their physicians need not hesitate to use a drug proven effective in preventing prostate cancer out of concern that it is likely to cause sexual dysfunction, say authors of a study conducted by the Southwest Oncology Group.

20 Jul 2007

Schering-Plough announces licensing of Acadesine

Schering-Plough Corporation has announced the worldwide licensing of acadesine, an investigational, potentially first-in-class adenosine regulating agent (ARA), from PeriCor Therapeutics, Inc., a privately held, specialty biopharmaceutical company.

20 Jul 2007

Certolizumab pegol effective for patients with Crohn's disease

Mayo Clinic researchers have found that Certolizumab pegol is an effective treatment for adults with Crohn's disease, according to two new studies.

19 Jul 2007

Tibotec Pharmaceuticals submits NDA for investigational HIV treatment

Tibotec Pharmaceuticals Ltd. has announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) for TMC125 (etravirine), an investigational non- nucleoside reverse transcriptase inhibitor (NNRTI), being studied for use with other antiretroviral (ARV) agents as a treatment for people infected with HIV- 1.

19 Jul 2007

New study explains placebo effect

Why do some people experience a “placebo effect” that makes them feel better when they receive a sham treatment they believe to be real — while other people don't respond at all to the same thing, or even feel worse?

19 Jul 2007

Researchers pinpoint brain region linked to placebo effect

Researchers have pinpointed a brain region central to the machinery of the placebo effect, the often controversial phenomenon in which a person's belief in the efficacy of a treatment such as a painkilling drug influences its effect.

19 Jul 2007

Quitting smoking with rimonabant

Using selective cannabinoid 1 (CB1) receptor antagonists such as rimonabant at a dose of 20 mg per day can help people quit smoking, can help them to remain abstinent, and can help prevent the weight gain that so often accompanies attempts at stopping smoking.

18 Jul 2007

Review of Rosiglitazone for type 2 diabetes mellitus

Little evidence supports using rosiglitazone (Avandia) to improve the quality or length of life among adults with diabetes, according to a systematic review of data by German researchers.

18 Jul 2007

Growth hormone for idiopathic short stature in children and adolescents

Growth hormone injections appear to boost height in extremely short, healthy children, according to a recent systematic review, but height gain appears to peak at about three inches - and those inches are expensive.

18 Jul 2007

FDA approves Extina for seborrheic dermatitis

Stiefel Laboratories, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its new drug application for Extina (ketoconazole) Foam, 2% for the treatment of seborrheic dermatitis.

18 Jul 2007

Paracetamol for pain relief after surgical removal of lower wisdom teeth

The commonly used and inexpensive analgesic acetaminophen (Tylenol or paracetamol) is an effective pain reliever after surgical removal of lower wisdom teeth, according to a new systematic review of 21 studies.

18 Jul 2007

COPD patients taking inhaled steroids are at greater risk for severe pneumonia

Patients with Chronic Obstructive Pulmonary Disease (COPD) are increasingly being prescribed inhaled corticosteroids to control exacerbations of the disease, but a new study finds that the anti-inflammatory drugs increase the chances that these patients will be hospitalized for pneumonia.

17 Jul 2007

Biota and MedImmune announce clinical trial for respiratory syncytial virus antiviral drug

Biota Holdings Limited and MedImmune Inc. today announced the start of a Phase Ia clinical trial for their respiratory syncytial virus (RSV) antiviral drug, BTA9881, with the goal of providing a treatment for RSV-infected infants and adults.

17 Jul 2007